Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential

Radiotherapy and Oncology

Volumn 110, Issue 2, 2014, Pages 362-369

  Koi, Lydia ^a,b   Bergmann, Ralf ^b   Brüchner, Kerstin ^a,b,c   Pietzsch, Jens ^b,d   Pietzsch, Hans Jürgen ^b,d   Krause, Mechthild ^a,b,c,e   Steinbach, Jörg ^b,d   Zips, Daniel ^a,b,f   Baumann, Michael ^a,b,c,e  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Helmholtz Zentrum Dresden Rossendorf   (Germany)

^c INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cetuximab; Combined treatment; Epidermal growth factor receptor (EGFR) inhibition; Radioimmunotherapy; Radiotherapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; YTTRIUM 90; EGFR PROTEIN, HUMAN; IMMUNOTOXIN; ISOTHIOCYANIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; N-(2-AMINO-3-(4-ISOTHIOCYANATOPHENYL)PROPYL)CYCLOHEXANE-1,2-DIAMINE-N,N',N',N'',N''-PENTAACETIC ACID; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CANCER GROWTH; CONTROLLED STUDY; DERMATITIS; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; IN VIVO STUDY; ISOTOPE LABELING; LIVER HISTOLOGY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIOIMMUNOTHERAPY; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; HUMAN; IMMUNOLOGY; NUDE MOUSE; RANDOMIZATION; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTOXINS; ISOTHIOCYANATES; MALE; MICE; MICE, NUDE; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 84896396028     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.12.001     Document Type: Article

References (37)

1. M. Baumann, M. Krause, and R. Hill Exploring the role of cancer stem cells in radioresistance Nat Rev Cancer 8 2008 545 554 (Pubitemid 351881850)
2. J. Kummermehr, and K. Trott Tumour stem cells C.S. Potten, Stem cells 1997 Academic Press Limited London 363 400
3. M. Krause, A. Yaromina, W. Eicheler, U. Koch, and M. Baumann Cancer stem cells: targets and potential biomarkers for radiotherapy Clin Cancer Res 17 2011 7224 7229
4. U. Koch, M. Krause, and M. Baumann Cancer stem cells at the crossroads of current cancer therapy failures - radiation oncology perspective Semin Cancer Biol 20 2010 116 124
5. M. Baumann, M. Krause, H. Thames, K. Trott, and D. Zips Cancer stem cells and radiotherapy Int J Radiat Biol 85 2009 391 402
6. M. Krause, D. Zips, H.D. Thames, J. Kummermehr, and M. Baumann Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy Radiother Oncol 80 2006 112 122 (Pubitemid 44314014)
7. J. Mendelsohn Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy Clin Cancer Res 3 1997 2703 2707 (Pubitemid 28133130)
8. D.S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
9. K.K. Ang, B.A. Berkey, X. Tu, H.Z. Zhang, R. Katz, and E.H. Hammond et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 2002 7350 7356 (Pubitemid 36025259)
10. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137 (Pubitemid 33674041)
11. M. Baumann, M. Krause, E. Dikomey, K. Dittmann, W. Dörr, and U. Kasten-Pisula et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms Radiother Oncol 83 2007 238 248 (Pubitemid 46915540)
12. L. Milas, F.M. Fang, K.A. Mason, D. Valdecanas, N. Hunter, and M. Koto et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation Int J Radiat Oncol Biol Phys 67 2007 568 572 (Pubitemid 46108328)
13. K. Gurtner, Y. Deuse, R. Butof, K. Schaal, W. Eicheler, and R. Oertel et al. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression Radiother Oncol 99 2011 323 330
14. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578 (Pubitemid 43209104)
15. S. Nasu, K.K. Ang, Z. Fan, and L. Milas C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability Int J Radiat Oncol Biol Phys 51 2001 474 477 (Pubitemid 32884294)
16. M. Krause, C. Schutze, C. Petersen, N. Pimentel, F. Hessel, and A. Harstrick et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC Radiother Oncol 74 2005 109 115 (Pubitemid 40331867)
17. J.J. Caudell, S.M. Sawrie, S.A. Spencer, R.A. Desmond, W.R. Carroll, and G.E. Peters et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment Int J Radiat Oncol Biol Phys 71 2008 676 681
18. P.K. Borjesson, E.J. Postema, R. de Bree, J.C. Roos, C.R. Leemans, and K.J. Kairemo et al. Radioimmunodetection and radioimmunotherapy of head and neck cancer Oral Oncol 40 2004 761 772 (Pubitemid 39061090)
19. M.J. Burdick, D. Neumann, B. Pohlman, C.A. Reddy, R.D. Tendulkar, and R. Macklis External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma Int J Radiat Oncol Biol Phys 79 2011 1124 1130
20. F. Buchegger, A. Roth, A. Allal, Y.M. Dupertuis, D.O. Slosman, and A.B. Delaloye et al. Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy Ann N Y Acad Sci 910 2000 263 269 [discussion 9-70]
21. F. Buchegger, A. Rojas, A.B. Delaloye, C.A. Vogel, R.O. Mirimanoff, and P. Coucke et al. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice Cancer Res 55 1995 83 89
22. A. Johansson, D. Eriksson, A. Ullen, P.O. Lofroth, L. Johansson, and K. Riklund-Ahlstrom et al. The combination of external beam radiotherapy and experimental radioimmunotargeting with a monoclonal anticytokeratin antibody Cancer 94 2002 1314 1319 (Pubitemid 34150895)
23. D. Eriksson, H.M. Joniani, A. Sheikholvaezin, P.O. Lofroth, L. Johansson, and K. Riklund Ahlstrom et al. Combined low dose radio- and radioimmunotherapy of experimental HeLa Hep 2 tumours Eur J Nucl Med Mol Imaging 30 2003 895 906 (Pubitemid 36734210)
24. M. Saki, M. Toulany, W. Sihver, M. Zenker, J.M. Heldt, and B. Mosch et al. Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro Strahlenther Onkol 188 2012 823 832
25. A. Yaromina, D. Zips, H.D. Thames, W. Eicheler, M. Krause, and A. Rosner et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies Radiother Oncol 81 2006 122 129 (Pubitemid 44780780)
26. A. Yaromina, M. Krause, H. Thames, A. Rosner, M. Krause, and F. Hessel et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation Radiother Oncol 83 2007 304 310 (Pubitemid 46915546)
27. A. Yaromina, T. Kroeber, A. Meinzer, S. Boeke, H. Thames, and M. Baumann et al. Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts Int J Radiat Oncol Biol Phys 80 2011 1205 1213
28. A. Yaromina, H. Thames, X. Zhou, S. Hering, W. Eicheler, and A. Dorfler et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation Radiother Oncol 96 2010 116 122
29. F.R. Luo, Z. Yang, H. Dong, A. Camuso, K. McGlinchey, and K. Fager et al. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft Cancer Chemother Pharmacol 56 2005 455 464 (Pubitemid 41549146)
30. X. Wen, Q.P. Wu, S. Ke, L. Ellis, C. Charnsangavej, and A.S. Delpassand et al. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225 J Nucl Med 42 2001 1530 1537 (Pubitemid 32953134)
31. Z. Liu, Y. Liu, B. Jia, H. Zhao, X. Jin, and F. Li et al. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab Mol Cancer Ther 9 2010 2297 2308
32. M. Ingargiola, C. Dittfeld, R. Runge, M. Zenker, J.M. Heldt, and J. Steinbach et al. Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation Cytometry A 81 2012 865 873
33. T.E. Witzig, L.I. Gordon, F. Cabanillas, M.S. Czuczman, C. Emmanouilides, and R. Joyce et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 20 2002 2453 2463 (Pubitemid 34525730)
34. J. Saker, M. Kriegs, M. Zenker, J.M. Heldt, I. Eke, and H.J. Pietzsch et al. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks J Nucl Med 54 2013 416 423
35. U. Kasten-Pisula, J. Saker, W. Eicheler, M. Krause, A. Yaromina, and S. Meyer-Staeckling et al. Cellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without EGFR amplification Int J Radiat Oncol Biol Phys 80 2011 1181 1188
36. H.J. Aerts, L. Dubois, L. Perk, P. Vermaelen, G.A. van Dongen, and B.G. Wouters et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET J Nucl Med 50 2009 123 131
37. G. Niu, Z. Li, J. Xie, Q.T. Le, and X. Chen PET of EGFR antibody distribution in head and neck squamous cell carcinoma models J Nucl Med 50 2009 1116 1123